Cover Image
市場調查報告書

血鐵沉著症(血色素沉著病) :全球臨床實驗趨勢

Hemochromatosis Global Clinical Trials Review, H2, 2017

出版商 GlobalData 商品編碼 339705
出版日期 內容資訊 英文 52 Pages
訂單完成後即時交付
價格
Back to Top
血鐵沉著症(血色素沉著病) :全球臨床實驗趨勢 Hemochromatosis Global Clinical Trials Review, H2, 2017
出版日期: 2017年09月15日 內容資訊: 英文 52 Pages
簡介

本報告提供血鐵沉著症臨床實驗相關之最新趨勢分析,提供您各地區的主要國家臨床實驗數量,臨床實驗的各階段進展,實驗對象採用狀況,有潛力的贊助商,各企業和研究機關的研究進展,以及潛力藥劑比較等資訊。

簡介

  • 血鐵沉著症
  • 本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 亞太地區主要5國的臨床實驗數量
    • 歐洲主要5國的臨床實驗數量
    • 北美主要國家的臨床實驗數量
    • 中東·非洲的主要5個國家臨床實驗數量
    • 中南美主要國家的臨床實驗數量

G7各國臨床實驗數量:遺傳性疾病治療藥臨床實驗上血鐵沉著症的比例

G7各國的各階段臨床實驗數量

G7各國臨床實驗數量:各進展狀況

E7各國臨床實驗數量:遺傳性疾病治療藥臨床實驗上血鐵沉著症的比例

E7各國的各階段臨床實驗數量

E7各國臨床實驗數量:各進展狀況

各階段臨床實驗數量

  • 進行中的臨床實驗:各階段

各進展狀況臨床實驗數量

臨床實驗的目標達成情形

未完成的臨床實驗數量

一定期間所採用的實驗對象

贊助商類別的臨床實驗數量

有潛力的贊助商

血鐵沉著症治療藥臨床實驗主要的參與企業

有潛力的藥劑

臨床實驗簡介

  • 主要企業臨床實驗概要
    • Novartis AG
    • Lipomed AG
    • OPIS s.r.l.
  • 有代表性的研究機關·醫院臨床實驗概要
    • The Children's Hospital Los Angeles
    • Annamalai University
    • Boston Children's Hospital
    • Centre Hospitalier Universitaire de Rennes
    • Innsbruck Medical University
    • King's College London
    • Maastricht University Medical Center
    • Murdoch Childrens Research Institute
    • National Heart, Lung, and Blood Institute
    • St. Jude Children's Research Hospital, Inc.

5個有代表性的臨床實驗簡介

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC4554CTIDB

GlobalData's clinical trial report, "Hemochromatosis Global Clinical Trials Review, H2, 2017" provides an overview of Hemochromatosis clinical trials scenario. This report provides top line data relating to the clinical trials on Hemochromatosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 3
  • Report Guidance 4
  • GlobalData Clinical Trials Report Coverage 5
  • Clinical Trials by Region 6
  • Clinical Trials and Average Enrollment by Country 7
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
  • Top Five Countries Contributing to Clinical Trials in Europe 11
  • Top Countries Contributing to Clinical Trials in North America 12
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
  • Top Countries Contributing to Clinical Trials in Central and South America 14
  • Clinical Trials by G7 Countries: Proportion of Hemochromatosis to Genetic Disorders Clinical Trials 15
  • Clinical Trials by Phase in G7 Countries 16
  • Clinical Trials in G7 Countries by Trial Status 17
  • Clinical Trials by E7 Countries: Proportion of Hemochromatosis to Genetic Disorders Clinical Trials 18
  • Clinical Trials by Phase in E7 Countries 19
  • Clinical Trials in E7 Countries by Trial Status 20
  • Clinical Trials by Phase 21
  • In Progress Trials by Phase 22
  • Clinical Trials by Trial Status 23
  • Clinical Trials by End Point Status 24
  • Subjects Recruited Over a Period of Time 25
  • Clinical Trials by Sponsor Type 26
  • Prominent Sponsors 27
  • Top Companies Participating in Hemochromatosis Therapeutics Clinical Trials 28
  • Prominent Drugs 29
  • Clinical Trial Profile Snapshots 30

Appendix 50

  • Abbreviations 50
  • Definitions 50
  • Research Methodology 51
  • Secondary Research 51
  • About GlobalData 52
  • Contact Us 52
  • Source 52

List of Tables

List of Tables

  • Hemochromatosis Therapeutics, Global, Clinical Trials by Region, 2017* 6
  • Hemochromatosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Hemochromatosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
  • Hemochromatosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 10
  • Hemochromatosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 11
  • Hemochromatosis Therapeutics Clinical Trials, North America, Top Countries, 2017* 12
  • Hemochromatosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 13
  • Hemochromatosis Therapeutics Clinical Trials, Central and South America, Top Countries, 2017* 14
  • Proportion of Hemochromatosis to Genetic Disorders Clinical Trials, G7 Countries (%), 2017* 15
  • Hemochromatosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16
  • Hemochromatosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 17
  • Proportion of Hemochromatosis to Genetic Disorders Clinical Trials, E7 Countries (%), 2017* 18
  • Hemochromatosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 19
  • Hemochromatosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 20
  • Hemochromatosis Therapeutics, Global, Clinical Trials by Phase, 2017* 21
  • Hemochromatosis Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 22
  • Hemochromatosis Therapeutics, Global, Clinical Trials by Trial Status, 2017* 23
  • Hemochromatosis Therapeutics Clinical Trials, Global, by End Point Status, 2017* 24
  • Hemochromatosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 25
  • Hemochromatosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 26
  • Hemochromatosis Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 27
  • Hemochromatosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 28
  • Hemochromatosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 29

List of Figures

List of Figures

  • Hemochromatosis Therapeutics, Global, Clinical Trials by Region (%), 2017* 6
  • Hemochromatosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 7
  • Hemochromatosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
  • Hemochromatosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 10
  • Hemochromatosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 11
  • Hemochromatosis Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 12
  • Hemochromatosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 13
  • Proportion of Hemochromatosis to Genetic Disorders Clinical Trials, G7 Countries (%), 2017* 15
  • Hemochromatosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16
  • Hemochromatosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 17
  • Proportion of Hemochromatosis to Genetic Disorders Clinical Trials, E7 Countries (%), 2017* 18
  • Hemochromatosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 19
  • Hemochromatosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 20
  • Hemochromatosis Therapeutics, Global, Clinical Trials by Phase (%), 2017* 21
  • Hemochromatosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 22
  • Hemochromatosis Therapeutics, Global, Clinical Trials by Trial Status, 2017* 23
  • Hemochromatosis Therapeutics Clinical Trials, Global, by End Point Status, 2017* 24
  • Hemochromatosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 25
  • Hemochromatosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 26
  • Hemochromatosis Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 27
  • Hemochromatosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 28
  • Hemochromatosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 29
  • GlobalData Methodology 51
Back to Top